Tech Company Financing Transactions
Prelude Therapeutics Funding Round
OrbiMed and private investors joined a $60 million Series B funding round for Prelude Therapeutics. The round was recorded on 6/13/2019.
Transaction Overview
Company Name
Announced On
6/13/2019
Transaction Type
Venture Equity
Amount
$60,000,000
Round
Series B
Investors
OrbiMed (Lead Investor)
Proceeds Purpose
Proceeds from the Series B financing will be used to advance Prelude's proprietary PRMT5 inhibitor, PRT543, through proof of concept clinical studies. PRT543 is in a parallel dose escalation Phase 1 clinical trial for solid tumors, myeloid malignancies and lymphomas.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
200 Powder Mill Rd.
Wilmington, DE 19803
USA
Wilmington, DE 19803
USA
Phone
Website
Email Address
Overview
Prelude (Nasdaq: PRLD) was founded in 2016 with the vision of bringing together the energy and collaborative culture of a start-up environment with experience in developing cancer medicines to create a next generation cancer drug discovery company.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Kris Vaddi
Chief Financial Officer
Brian Piper
Chief Medical Officer
David Mauro
Chief Scientific Officer
Peggy Scherle
Executive Vice President
Andrew Combs
Vice President
Madhu Pudipeddi
VP - R & D
Aimee Crombie
VP - Regulatory Affairs
Adam Shilling
Browse more venture capital transactions:
Prev: 6/13/2019: SKUPOS venture capital transaction
Next: 6/13/2019: Apollo venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to document every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs